US Supplement Label Compliance: A Practical Guide

US Supplement Label Compliance: A Practical Guide
  • Packaging & Labeling
Posted by ZOOMSHEAL On Nov 14 2026

Most supplement label problems are not caught by the FDA first — they are caught by a retailer, a customs broker, or a plaintiff's attorney. A label that looks fine in a design file can fail on the shelf because a Supplement Facts panel is misformatted, a claim crosses into disease territory, or the manufacturer cannot produce the documentation behind the numbers. This guide covers what US law actually requires, which documents a buyer should collect, and where labels typically break.

What US law requires on a dietary supplement label

Dietary supplements are regulated as a category of food under the Federal Food, Drug, and Cosmetic Act, as amended by DSHEA (1994). Labeling requirements sit primarily in 21 CFR 101.36 (Supplement Facts), 21 CFR 101.4 (ingredient declarations), and 21 CFR 101.9 where general nutrition rules apply. The mandatory statements are specific:

  • Statement of identity — the common or usual name of the product, e.g., "Dietary Supplement."
  • Net quantity of contents — in avoirdupois or metric units, placed in the lower third of the principal display panel.
  • Supplement Facts panel — serving size, servings per container, and for each dietary ingredient: amount per serving and percent Daily Value where one exists. Proprietary blends must list total blend weight and each ingredient, with ingredients in descending order by weight (21 CFR 101.36(c)).
  • Other ingredients — listed in descending order of predominance by weight.
  • Allergen declaration — FALCPA requires major food allergens to be declared in plain language, either in the ingredient list or in a "Contains" statement.
  • Name and place of business — of the manufacturer, packer, or distributor, plus a contact address. A phone number or website is not a substitute for a physical address.
  • Domestic address requirement — a foreign manufacturer must list a US agent or distributor address.

Formatting is not cosmetic. Font size, bold rules, indentation, and the order of vitamins and minerals in the panel are prescribed. A panel that is visually close but structurally wrong is non-compliant.

Claims: the line that matters most

Structure/function claims describe how a nutrient affects normal body function ("supports immune health"). They are allowed without premarket FDA review, but they trigger two obligations: the manufacturer must have substantiation, and the label must carry the DSHEA disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Disease claims — anything implying treatment, prevention, or cure — convert the product into an unapproved drug. This is the most common enforcement trigger for warning letters and the most common basis for class-action suits. Health claims (a relationship between a substance and a disease or health condition) require an authorized claim or a qualified health claim with FDA-reviewed wording. A practical rule: if the claim names a condition, a drug, or a symptom, it needs regulatory review before it goes on artwork.

For products sold in California, Prop 65 adds a separate layer. Warning requirements depend on exposure to listed substances, and the safe harbor thresholds are low. Botanical ingredients, heavy metal carryover, and lead in some raw materials are recurring Prop 65 issues. Ask for a Prop 65 assessment rather than assuming a supplement is exempt.

Documents a buyer should collect before approving artwork

Label compliance is a documentation exercise as much as a design one. The following should be on file before a purchase order is released:

  • Certificate of Analysis (CoA) for each finished lot, covering identity, potency, and microbiology, plus heavy metals by USP <232>/<233> and, where applicable, disintegration by USP <711>.
  • Specification sheet signed by the manufacturer, stating the assay method and acceptance range.
  • Ingredient and allergen review mapped to the label's "Contains" statement and other-ingredient list.
  • Stability data per ICH Q1A(R2) — typically real-time at 25°C/60% RH with accelerated conditions — supporting the potency and "best by" date on the label.
  • Label review record showing who approved the final artwork and against which checklist.
  • Facility registration and GMP evidence — 21 CFR 111 compliance, with the most recent audit result. Third-party certifications such as NSF, USP, or Informed Choice are useful signals but do not replace the 21 CFR 111 obligation.

For imported finished goods, the importer of record carries additional duties under the FDA Food Safety Modernization Act Foreign Supplier Verification Program (21 CFR 117), and Prior Notice (21 CFR 1005) must be filed for each shipment. These are importer obligations, not manufacturer ones — a supplier claiming to "handle" them should be able to show how.

Where labels fail: common failure modes

Most compliance failures fall into a small number of patterns. Reviewing for these specifically is faster than a general read-through.

  • Supplement Facts arithmetic — percent Daily Value calculated against the wrong reference amount, or a blend total that does not equal the sum of its parts.
  • Overages unaccounted for — manufacturers often add 10–30% overage (a typical industry range) to compensate for degradation over shelf life. The label must state the amount at the end of shelf life, not the amount at manufacture. If the label says 500 mg and the formula uses 600 mg to hit that at expiry, the paperwork should explain it.
  • Claim creep in marketing copy — compliant label, non-compliant website, insert, or Amazon bullet. Enforcement looks at the whole labeling package.
  • Missing or misplaced disclaimer — the DSHEA disclaimer must be prominent and appear with the structure/function claim, not buried in fine print.
  • Allergen gaps — shared lines without a validated cleaning procedure, or a "Contains" statement that omits a sub-ingredient.
  • Stale artwork — formula changed, label not updated; or a "new and improved" callout that no longer matches the panel.
  • Foreign-language versions — translated labels that drift from the English original, especially on claims.

Questions to ask your supplier

These questions separate manufacturers who manage compliance from those who format a panel and move on. Ask them before the first production run, and again at annual review.

  • Who reviews our label against 21 CFR 101.36, and can we see the completed review checklist?
  • Does the quoted potency reflect the amount at manufacture or at end of shelf life, and what overage is built in?
  • Can you provide a stability protocol and the most recent real-time data for this formula?
  • Which third-party lab runs your CoAs, and can we see a sample report with methods listed?
  • How do you handle allergen cross-contact on shared equipment, and what cleaning validation exists?
  • What is your process for change control when a raw material source changes?
  • Are you registered with FDA, and when was your last 21 CFR 111 audit — internal or third-party?
  • For capsules, who controls the shell composition and the disintegration testing? See capsule manufacturing for the parameters that affect label claims.

Frequently asked questions

Does the FDA approve supplement labels before sale?

No. There is no premarket approval for dietary supplement labels. The manufacturer and brand owner are responsible for compliance, and FDA reviews labels after products are on the market — typically in response to a complaint, an inspection, or a targeted enforcement sweep. That makes internal review the only real gate.

How long does a label review take, and what does it cost?

For a single-SKU review by an experienced regulatory consultant, turnaround is commonly one to three weeks, and fees typically fall in the low hundreds to low thousands of US dollars per label depending on complexity and claim review. These are typical industry ranges, not quotes. Budget extra time if claims need substantiation review or if the product is sold in California.

Can I put a structure/function claim on the front panel?

Yes, provided the claim is truthful, not misleading, and substantiated, and the DSHEA disclaimer appears on the label. The disclaimer should be placed with the claim or elsewhere on the label with equal prominence. Front-panel claims get more scrutiny from regulators and plaintiffs, so keep the wording conservative and documented.

What is required for a proprietary blend?

Under 21 CFR 101.36(c), the panel must state the total weight of the blend and list each dietary ingredient in the blend in descending order by weight. Individual ingredient amounts may be omitted, but the total must be accurate. "Proprietary blend" is not a way to avoid listing ingredients — only their individual quantities.

Do I need a US address if my manufacturer is overseas?

Yes. The label must show a name and place of business for the manufacturer, packer, or distributor, and for imported products that is typically the US importer or distributor with a domestic address. A website or email alone does not satisfy the requirement. The importer also carries FSVP and Prior Notice obligations for each shipment.

What to do next

Start with the documents, not the design. Request the CoA format, stability protocol, allergen control procedure, and label review checklist from your manufacturer before approving artwork, then commission an independent review of the final panel against 21 CFR 101.36. If you are evaluating a new production partner, include label compliance in the qualification audit alongside GMP status — the two fail together more often than either fails alone. For buyers moving from concept to production, OEM manufacturing partners should be able to show this paperwork as a matter of routine.

Related Manufacturing Services

Featured News